ES2141229T3 - Productos farmaceuticos de proteinas y peptidos modificados. - Google Patents

Productos farmaceuticos de proteinas y peptidos modificados.

Info

Publication number
ES2141229T3
ES2141229T3 ES94914152T ES94914152T ES2141229T3 ES 2141229 T3 ES2141229 T3 ES 2141229T3 ES 94914152 T ES94914152 T ES 94914152T ES 94914152 T ES94914152 T ES 94914152T ES 2141229 T3 ES2141229 T3 ES 2141229T3
Authority
ES
Spain
Prior art keywords
peptides
amino acid
ctp units
pharmaceutical products
partial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94914152T
Other languages
English (en)
Inventor
Irving Boime
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Application granted granted Critical
Publication of ES2141229T3 publication Critical patent/ES2141229T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

SE UTILIZAN UNIDADES DE CTP "PARCIALES" Y "COMPLETAS" PARA MODIFICAR PROTEINAS Y PEPTIDOS BIOLOGICAMENTE ACTIVOS PARA ALTERAR SUS PATRONES DE SEPARACION. LAS UNIDADES DE CTP "COMPLETAS" TIENE LA SECUENCIA DE AMINOACIDOS QUE SE ENCUENTRA EN LAS POSICIONES 112-118 A LA POSICION 145 DE LA {BE}-SUBUNIDAD DE GONADOTROPINA CORIONICA HUMANA; LAS UNIDADES DE CTP "PARCIALES" TIENEN AL MENOS UN AMINOACIDO MENOS EN LA REGION DE LA POSICION 118-145 INCLUSIVE. VARIAS DE ESTAS UNIDADES DE CTP CONTIENE SUSTITUCIONES DE AMINOACIDOS 1-5-MODERADAS QUE NO DESTRUYEN SU ACTIVIDAD. ENTRE LOS PEPTIDOS Y PROTEINAS ADECUADOS QUE SE PUEDEN MODIFICAR DE ESTA MANERA SE ENCUENTRAN VARIAS HORMONAS Y CITOQUINAS.
ES94914152T 1993-04-20 1994-04-13 Productos farmaceuticos de proteinas y peptidos modificados. Expired - Lifetime ES2141229T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4986993A 1993-04-20 1993-04-20

Publications (1)

Publication Number Publication Date
ES2141229T3 true ES2141229T3 (es) 2000-03-16

Family

ID=21962168

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94914152T Expired - Lifetime ES2141229T3 (es) 1993-04-20 1994-04-13 Productos farmaceuticos de proteinas y peptidos modificados.

Country Status (14)

Country Link
EP (1) EP0695307B1 (es)
JP (2) JP4156024B2 (es)
AT (1) ATE187740T1 (es)
AU (1) AU687053B2 (es)
CA (1) CA2160800C (es)
DE (1) DE69422169D1 (es)
ES (1) ES2141229T3 (es)
FI (1) FI954978A (es)
GR (1) GR3032775T3 (es)
NO (1) NO954188L (es)
NZ (1) NZ265529A (es)
PT (1) PT695307E (es)
WO (1) WO1994024148A1 (es)
ZA (1) ZA942729B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997871A (en) * 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6319504B1 (en) * 1996-06-24 2001-11-20 University Of Maryland Biotechnology Institute Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US7994278B1 (en) * 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
JP2001333772A (ja) 2000-04-25 2001-12-04 Washington Univ 可変性の活性を有する単鎖稔性ホルモン
EP1342730B1 (en) * 2000-12-11 2006-03-15 Cheil Jedang Corporation Fusion protein having the enhanced in vivo activity of erythropoietin
US6987172B2 (en) 2001-03-05 2006-01-17 Washington University In St. Louis Multifunctional single chain glycoprotein hormones comprising three or more β subunits
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
CN104487082A (zh) 2012-04-19 2015-04-01 奥普科生物制品有限公司 长效胃泌酸调节素变体及其生产方法
BR122020018510B1 (pt) 2012-11-20 2023-03-14 Opko Biologics Ltd Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia
WO2014159813A1 (en) 2013-03-13 2014-10-02 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
CN107438623B (zh) * 2014-12-10 2023-07-14 Opko生物科学有限公司 长效的ctp修饰的生长激素多肽的制备方法
WO2016203482A2 (en) 2015-06-19 2016-12-22 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
HUE064463T2 (hu) 2016-07-11 2024-03-28 Opko Biologics Ltd Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654324A (en) * 1981-08-27 1987-03-31 Eli Lilly And Company Human proinsulin pharmaceutical formulations
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
AU648020B2 (en) * 1989-02-21 1994-04-14 Washington University Modified forms of reproductive hormones
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
JPH04156024A (ja) * 1990-10-19 1992-05-28 Fujitsu Ltd サブレート交換方式

Also Published As

Publication number Publication date
ZA942729B (en) 1995-01-09
NO954188D0 (no) 1995-10-19
FI954978A (fi) 1995-11-15
JP4156024B2 (ja) 2008-09-24
DE69422169D1 (de) 2000-01-20
WO1994024148A1 (en) 1994-10-27
NO954188L (no) 1995-12-19
EP0695307A1 (en) 1996-02-07
GR3032775T3 (en) 2000-06-30
EP0695307B1 (en) 1999-12-15
ATE187740T1 (de) 2000-01-15
EP0695307A4 (en) 1996-08-21
NZ265529A (en) 1998-01-26
CA2160800C (en) 2010-06-01
CA2160800A1 (en) 1994-10-27
AU6633194A (en) 1994-11-08
FI954978A0 (fi) 1995-10-18
AU687053B2 (en) 1998-02-19
JPH08509218A (ja) 1996-10-01
PT695307E (pt) 2000-05-31
JP2008133295A (ja) 2008-06-12

Similar Documents

Publication Publication Date Title
ES2141229T3 (es) Productos farmaceuticos de proteinas y peptidos modificados.
NO941186D0 (no) Hormonanaloger med multiple CTP-forlengelser
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
LU91342I2 (fr) Byetta-exénatide
ATE257859T1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
ATE179429T1 (de) Cytokine dämpfende substanzen
DE3875108T2 (de) Physiologisch aktives polypeptid und pharmazeutische komposition.
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
ATE218616T1 (de) Humanes zirkulierendes cytokin cc-1
ATE216234T1 (de) Zusammensetzungen aus aminosäure zur behandlung von infektionen
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
DE69325512D1 (de) Verwendung von remacemid zur behandlung des morbus parkinson
DE3585936D1 (de) Biologisch aktive peptide, deren verfahren zur herstellung und pharmazeutische zusammensetzungen.
TH18599EX (th) ยาที่เป็นโปรตีนและเพทไทด์ดัดแปลง
TH18599A (th) ยาที่เป็นโปรตีนและเพทไทด์ดัดแปลง
ES2080326T3 (es) Proteinas similares a ancrod, su obtencion y empleo.
MX9604539A (es) Aminoacidos modificados para la distribucion de farmaco.
TH14767EX (th) กระบวนการสำหรับแยกเอารีคอมบิแนนท์โปรตีนในรูปที่ออกฤทธิ์ทางชีววิทยาออกมาจากสารละลายที่มีโปรตีนที่ไม่ออกฤทธิ์อยู่ด้วย

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 695307

Country of ref document: ES